DFTX
DFTX
Definium Therapeutics, Inc.Company Information
Recommendation Details
Healthcare holds up to 5 names drawn from Healthcare above $200M. Healthcare ranked on the positive head, composite factor and analyst rating. Positions are held for 6-21 days, each position carries a 20% stop-loss. Benchmark: S&P 500 Health Care (S5HLTH).
Company Description
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.